SkinMedica Launches Redness Relief CalmPlex™

CARLSBAD, Calif., Feb. 3, 2011 /PRNewswire/ -- SkinMedica, Inc., the fastest-growing professional skin care company in the United States, today announced that it is introducing a new, fast-acting anti-redness product, Redness Relief CalmPlex™—the biggest innovation in redness in over two decades.  It is the first and only non-prescription product clinically proven to reduce visible redness.    

(Photo: http://photos.prnewswire.com/prnh/20110203/NY41924 )

(Logo: http://photos.prnewswire.com/prnh/20100810/NY48207LOGO )

This revolutionary formula contains, CalmPlex™, a patented, nature-inspired ingredient that treats the underlying causes of redness by inhibiting the release of a key natural vasodilator as well as niacinamide which helps to strengthen the skin by supporting the barrier function.  

"Visible redness is a real and emotional burden for millions of people," commented SkinMedica Founder, Richard Fitzpatrick, MD.  "As dermatologists, we have been frustrated by the lack of effective approaches to reducing the appearance of redness.  Backed by solid science and clinical results, Redness Relief CalmPlex™ represents a truly novel advance in the skin aesthetics area."

Ideal for sensitive skin types, this non-comedogenic formula contains no added fragrance and offers relief and results to improve overall skin appearance by neutralizing unwanted redness.

CLINICAL STUDIES:

In multiple clinical studies, Redness Relief CalmPlex™ demonstrated efficacy in relieving visible redness and improving overall skin tone. SkinMedica Redness Relief CalmPlex™ demonstrated a 40% reduction in UV-induced redness in as early as 3 days. Redness Relief CalmPlex™ also provided significant reductions in chronic redness after 1 week with continued improvement through week twelve.

Physicians assessing the clinical study reported the following results after only four weeks:

• 43% reduction in appearance of visible redness
• 51% improvement in evenness of skin tone
• 49% improvement in overall severity

Participants in the study reported the following results at Week 4:

• 78% of subjects reported an improvement in overall condition
• 72% of subjects reported a reduction in visible redness
• High patient satisfaction; 100% of subjects liked the product

SkinMedica Redness Relief CalmPlex™ launched the second week of January and is available through licensed physicians and medically supervised spas. Visit SkinMedica.com for locations.

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. The Company markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The Company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum™ and hallmark TNS Recovery Complex®. The formulations in the Company's clinical skin care collection enhance skin appearance, reduce signs of aging and provide other skin care benefits.

SkinMedica's prescription products include VANIQA® (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the reduction of unwanted facial hair in women and EpiQuin® Micro Cream (4% hydroquinone) for hyperpigmentation, or "brown spots" that commonly result from aging, inflammation or sun exposure.

SkinMedica is based in Carlsbad, California. For more information, visit: www.skinmedica.com.

TNS Recovery Complex®, VANIQA®, EpiQuin® Micro, and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.

SOURCE SkinMedica, Inc.